BeiGene, Ltd. (BGNE): Price and Financial Metrics
BGNE Stock Summary
- BGNE has a market capitalization of $28,015,967,661 -- more than approximately 91.12% of US stocks.
- With a price/sales ratio of 90.7, BeiGene Ltd has a higher such ratio than 96.21% of stocks in our set.
- With a year-over-year growth in debt of 102.63%, BeiGene Ltd's debt growth rate surpasses 89.79% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to BeiGene Ltd are WDC, ZLAB, SRPT, XLRN, and EDIT.
- BGNE's SEC filings can be seen here. And to visit BeiGene Ltd's official web site, go to www.beigene.com.
BGNE Stock Price Chart Interactive Chart >
BGNE Price/Volume Stats
|Current price||$305.54||52-week high||$388.97|
|Prev. close||$307.81||52-week low||$136.48|
|Day high||$308.14||Avg. volume||307,063|
|50-day MA||$331.11||Dividend yield||N/A|
|200-day MA||$281.59||Market Cap||28.02B|
BeiGene, Ltd. (BGNE) Company Bio
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.
BGNE Latest News Stream
|Loading, please wait...|
BGNE Latest Social Stream
View Full BGNE Social Stream
Latest BGNE News From Around the Web
Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
BeiGene (BGNE) presents clinical data on tislelizumab, in combination with sitravatinib being jointly developed with Mirati Therapeutics (MRTX) at the American Association for Cancer Research ((AACR)) Annual Meeting 2021.Data presented were from two cohorts of Phase 1b trial in patients with unresectable or metastatic melanoma who were refractory or resistant to...
L1 resistant or refractory melanoma.
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from a planned interim analysis of the Phase 3 RATIONALE 303 trial of its anti-PD-1 antibody tislelizumab compared to docetaxel as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021. A supplemental biologics application (sBLA) based on these results from the RATIONALE 303 trial was accepted in March 2021 and is currently under regulatory review in China.
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc. (Mirati), were presented in two oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial (NCT03666143), in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patients with advanced platinum-resistant ovarian cancer (PROC).
BeiGene Ltd (NASDAQ: BGNE ) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental … Full story available on Benzinga.com
BGNE Price Returns
Continue Researching BGNEWant to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!